See more : Borosil Renewables Limited (BORORENEW.BO) Income Statement Analysis – Financial Results
Complete financial analysis of OKYO Pharma Limited (OKYO.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OKYO Pharma Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Graycliff Exploration Limited (GRYCF) Income Statement Analysis – Financial Results
- Marchex, Inc. (MCHX) Income Statement Analysis – Financial Results
- Volt Carbon Technologies Inc. (TORVF) Income Statement Analysis – Financial Results
- The Eastern Company (EML) Income Statement Analysis – Financial Results
- Haivision Systems Inc. (HAI.TO) Income Statement Analysis – Financial Results
OKYO Pharma Limited (OKYO.L)
About OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 990.55K | 132.86K | 407.48K | 2.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 319.14K | 391.76K | 590.68K | 333.62K | 1.28M | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 3.00K | 44.00K | 37.00K |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 319.14K | 391.76K | 590.68K | 333.62K | 1.28M | 1.42M | 0.00 | 1.00K | 3.00K | 44.00K | 37.00K |
| Other Expenses | 3.74M | 2.87M | 799.50K | 1.41M | 518.36K | 245.19K | 173.35K | 981.83K | 1.59M | 1.69M | 3.38M | 1.06M | -13.67M | -10.58M | 1.56M |
| Operating Expenses | 4.73M | 3.01M | 1.21M | 3.75M | 837.50K | 636.94K | 764.03K | 1.32M | 2.87M | 3.12M | 3.38M | 1.06M | -13.67M | -10.54M | 1.60M |
| Cost & Expenses | 4.73M | 3.01M | 1.21M | 3.75M | 837.50K | 636.94K | 764.03K | 1.32M | 2.87M | 3.12M | 3.38M | 1.06M | -13.67M | -10.54M | 1.60M |
| Interest Income | 0.00 | 0.00 | 37.85K | 0.00 | 0.00 | 3.55K | 8.60K | 11.68K | 0.00 | 61.35K | 13.00K | 88.00K | 1.00K | 266.00K | 174.00K |
| Interest Expense | 0.00 | 858.00 | 911.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.02K | 42.55K | 167.00 | -52.31M | 97.25K | 193.32K | 193.32K | -4.26M | 62.14K | 16.08K | 12.00K | -5.26M | -5.26M | -532.00K | 96.00K |
| EBITDA | -4.73M | -3.00M | -1.16M | -3.76M | -53.15M | -539.69K | -570.72K | -5.57M | -8.30M | -3.05M | -2.99M | -1.01M | 8.41M | 10.01M | -1.50M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.73M | -3.01M | -1.21M | -3.75M | -837.50K | -636.94K | -764.03K | -1.32M | -2.87M | -3.12M | -3.38M | -1.06M | 13.67M | 10.54M | -1.60M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -9.40K | -67.40K | -12.12K | -52.31M | 97.25K | 61.11K | -4.26M | -5.50M | 51.86K | -178.00K | 54.00K | -5.26M | -532.00K | 96.00K |
| Income Before Tax | -4.73M | -3.02M | -1.27M | -3.76M | -53.15M | -539.69K | -702.92K | -5.57M | -8.37M | -3.06M | -3.56M | -1.01M | 8.41M | 10.01M | -1.50M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -598.75K | -19.10K | -60.00K | -12.12K | 0.00 | 0.00 | -132.20K | 0.00 | -5.50M | 51.86K | -178.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -4.13M | -3.00M | -1.21M | -3.76M | -53.15M | -539.69K | -570.72K | -5.57M | -8.37M | -3.06M | -3.00M | -1.01M | 8.41M | 10.01M | -1.50M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.14 | 0.00 | 0.00 | -0.01 | -0.03 | -0.01 | -0.03 | 0.00 | 0.03 | 0.03 | -0.03 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | -0.14 | 0.00 | 0.00 | -0.01 | -0.03 | -0.01 | -0.03 | 0.00 | 0.02 | 0.03 | -0.03 |
| Weighted Avg Shares Out | 979.21M | 672.77M | 595.47M | 513.90M | 381.82M | 381.16M | 381.16M | 377.12M | 300.92M | 283.16M | 106.87M | 355.10M | 330.76M | 326.83M | 55.69M |
| Weighted Avg Shares Out (Dil) | 979.21M | 672.77M | 595.47M | 513.90M | 381.82M | 381.16M | 381.16M | 377.12M | 300.92M | 283.16M | 106.87M | 355.10M | 355.00M | 351.09M | 55.69M |
Source: https://incomestatements.info
Category: Stock Reports